Company
Teva Pharmaceuticals
781 Legal Matters
190
147
444
OverviewLitigationPatentsTrademarksStatisticsNews

Teva Pharmaceuticals Company IP Overview

Practice Areas
Recent StatisticsView All
Subscription-Only
View Concierge Program
PatentsView All
Patents Issued Each Year
TrademarksView All
Trademark Applications Filed Each Year
LitigationView All
Cases Filed Each Year
NewsView All
Pedram Sameni
•
Patexia Insight 218: A Deep Dive into the Top Pharmaceutical Companies in ANDA Litigation
Pedram Sameni
•
Sep 12, 2024
In the pharmaceutical industry, innovation drives progress, but intense legal battles, particularly in ANDA (Abbreviated New Drug Application) litigation, shape... Read More
Mikele Bicolli
•
UroGen Pharma Faces Paragraph IV Challenge as Teva Pursues Generic Jelmyto Approval
Mikele Bicolli
•
Mar 1, 2024
Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted... Read More
Mikele Bicolli
•
Corcept Therapeutics Faces Share Price Plunge After Losing Teva Patent Battle
Mikele Bicolli
•
Jan 2, 2024
  Corcept Therapeutics experienced a significant drop in its stock value by 27% on Tuesday following an unfavorable verdict in... Read More
Practice Areas
PatentsView All
Patents Issued Each Year
LitigationView All
Cases Filed Each Year
Recent StatisticsView All
Subscription-Only
View Concierge Program
TrademarksView All
Trademark Applications Filed Each Year
NewsView All
Pedram Sameni
•
Patexia Insight 218: A Deep Dive into the Top Pharmaceutical Companies in ANDA Litigation
Pedram Sameni
•
Sep 12, 2024
In the pharmaceutical industry, innovation drives progress, but intense legal battles, particularly in ANDA (Abbreviated New Drug Application) litigation, shape... Read More
Mikele Bicolli
•
UroGen Pharma Faces Paragraph IV Challenge as Teva Pursues Generic Jelmyto Approval
Mikele Bicolli
•
Mar 1, 2024
Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted... Read More
Mikele Bicolli
•
Corcept Therapeutics Faces Share Price Plunge After Losing Teva Patent Battle
Mikele Bicolli
•
Jan 2, 2024
  Corcept Therapeutics experienced a significant drop in its stock value by 27% on Tuesday following an unfavorable verdict in... Read More